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Abstract: Amelogenins are extracellular matrix proteins that, under physiological conditions, 
self-assemble into globular aggregates up to micron-sizes. Studies with periodontal ﬁ  broblasts 
indicate that attachment to these structures increases the endogenous secretion of multiple growth 
factors and cell proliferation. Pre-clinical and clinical studies indicate that cutaneous wounds 
beneﬁ  t from treatment with amelogenins. A randomized controlled trial (RCT) involving patients 
with hard-to-heal venous leg ulcers (VLUs) (ie, ulcers with a surface area 10 cm2 and duration 
of 6 months) showed that the application of amelogenin (Xelma®, Molnlycke Health Care, 
Gothenburg, Sweden) as an adjunct treatment to compression results in signiﬁ  cant reduction in 
ulcer size, improvement in the state of ulcers, reduced pain, and a larger proportion of ulcers with 
low levels of exudate, compared with treatment with compression alone. Amelogenin therapy was 
also shown to be safe to use in that there were no signiﬁ  cant differences in adverse events noted 
between patients treated with amelogenin plus compression and those treated with compression 
alone. Case study evaluations indicate that the beneﬁ  ts of amelogenin therapy demonstrated in 
the RCT are being repeated in “real life” situations and that amelogenin therapy may also have 
a role to play in the treatment of other wound types such as diabetic foot ulcers.
Keywords: extracellular matrix, amelogenin, venous leg ulcers, diabetic foot ulcers, pyoderma 
gangrenosum
Introduction
Venous leg ulcers (VLUs) pose a serious clinical dilemma and an economic burden 
on health services. They are frequently associated with morbidity, pain, and decreased 
quality of life in affected patients. About 60% of patients with VLUs will experience 
pain related to their wounds (Hofman et al 1997), which may be constant or intermittent 
(Ryan et al 2003). The pain can cause depression and a feeling of constant tiredness 
(Price et al 2007) and may also interfere with the healing process (Soon and Acton, 
2006). These patients may have highly exuding ulcers that could lead to wound malo-
dour and its associated social stigma, resulting in further detrimental psychological 
effects. VLUs also provide an ideal environment for the growth of pathogenic bac-
teria, with wound colonisation/infection prevalent in immunocompromised patients. 
The management of these problems is both time consuming and expensive. VLUs 
are associated with signiﬁ  cant treatment costs (bandages, dressings, and adjunctive 
therapies) and nursing resource.
About 1%–2% of the whole population (Anderson 2006) and 3%–5% of the popula-
tion over 65 years of age (Mekkes et al 2003) will suffer from a leg ulcer during their 
lifetime. However, in a typical Western population where the average age is steadily Clinical Interventions in Aging 2008:3(2) 264
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increasing, the burden placed upon the health economy by 
VLUs looks set to increase proportionally. Cost effective 
treatment of VLUs is therefore vital.
Back in the 1960s, George Winter published his landmark 
paper in which he demonstrated that, contrary to the belief at 
the time that wounds should be allowed to dry out and form 
scabs to promote healing, wounds heal faster if kept moist 
(Winter et al 1962). Since then, the use of “cheap” gauze 
dressings and bandages has given way to more technically 
advanced dressings, such as foams and hydroﬁ  bres, which 
interact with and manage the wound environment. The use of 
these now established dressings in combination with the “gold 
standard” high compression therapy is generally effective in 
the management of VLUs, although up to 20% of VLUs fail 
to heal despite being treated with this regime (White 2006).
The reasons for the lack of response to treatment of hard-
to-heal VLUs have not yet been fully elucidated, although 
scientiﬁ  c and clinical research indicates that, instead of 
progressing through the four distinct but overlapping phases 
of healing (hemostasis, inﬂ  ammation, proliferation, and 
remodeling), these wounds become ‘stuck’ in a prolonged 
inﬂ  ammatory phase (Timmons 2006).
Control of the processes within the phases of wound 
healing is complex and involves the interaction of several 
different cell types (eg, neutrophils, lymphocytes, macro-
phages, ﬁ  broblasts), regulatory mediators (eg, cytokines, 
growth factors), extracellular matrix (ECM) components (eg, 
ﬁ  bronectin, ﬁ  brin, collagen, elastin, laminin, proteoglycans, 
glycosaminoglycans), proteases and their inhibitors (eg, 
matrix metalloproteinases [MMPs] and tissue inhibitors of 
metalloproteinases [TIMPs]) (Schultz et al 2005). Early in 
the wound healing process there is a requirement for the 
synthesis and deposition of ECM proteins such as ﬁ  brin 
and ﬁ  bronectin (Hodde and Johnson 2007) and a sub-set 
of matrix proteins that are expressed transiently during the 
wound healing process, eg, galectins, osteopontin, SPARC, 
syndecans, tenascins, thrombospondins, and vitronectin 
(Agren and Werthen 2007). All of these matrix proteins form 
a provisional wound matrix which provides a scaffold that 
directs cells into the wound as well as stimulating them to 
proliferate, differentiate and synthesise new ECM to facili-
tate the proliferation and remodeling phases of the healing 
process (Schultz et al 2005).
In many chronic wounds, however, the normal healing 
process is disrupted by extensive tissue damage accompanied 
by biochemical and cellular imbalances, or by an underlying 
pathological state (eg, venous insufﬁ  ciency) that can impair or 
even prevent healing. For example, in the case of hard-to-heal 
VLUs, venous hypertension causes disturbed microcirculation 
and pathological changes to capillaries, which ultimately locks 
the condition in a self-amplifying cascade with persistent 
elevated levels of pro-inﬂ  ammatory cytokines and proteases 
that appear to degrade the ECM components, growth factors 
and receptors that are essential for healing (Agren et al 2000; 
Schultz et al 2005) The ECM is a vital component of the healing 
process; intact or fragmented ECM molecules play a central 
role in modulating cells through transduction of a variety 
of signaling mechanisms (Agren et al 2000). Additionally, 
ECM plays a role in angiogenesis, recruitment of circulating 
progenitor cells, rapid scaffold degradation and constructive 
remodeling of damaged or missing tissues (Badylak 2002). In 
studies investigating the mechanisms that lead to venous leg 
ulceration, it has been demonstrated that intrinsic ECM degra-
dation processes, prevalent in this disease state, are caused by 
the MMP family of enzymes (Herouy et al 2000; Bogaczewicz 
et al 2005). Speciﬁ  cally, it has been shown that ﬁ  bronectin is 
absent in the base of nonhealing ulcers (Herrick et al 1992) 
although ﬁ  broblasts in such wounds synthesize ﬁ  bronectin 
normally (Herrick et al 1996). It is hypothesized, therefore, that 
the reduced levels of ﬁ  bronectin in nonhealing ulcers is due to 
excessive degradation of ﬁ  bronectin by proteases in the ulcers, 
rather than decreased synthesis (Agren and Werthen 2007). On 
this basis, there is a clear need for new and advanced interven-
tions that can interact with hard-to-heal VLUs that are locked 
in the inﬂ  ammatory phase of the healing process and progress 
them to the subsequent proliferative stage of the process.
A speciﬁ  c focus of attention for the development of 
advanced wound therapies should be (and has been in recent 
years) the ECM, either by inducing its synthesis through 
growth factors, preventing its damage with sacriﬁ  cial proteins 
or replacing it with autologous/homologous ECM proteins or 
their like. One mechanism by which this can be achieved is 
to provide hard-to-heal ulcers with surrogate ECMs which, 
although not homologous to the patient’s own ECM, will 
provide transient structures that allow cellular adhesion and 
facilitate tissue regeneration by advancing the wounds to the 
proliferative phase of the healing process. Amelogenin has 
been identiﬁ  ed as an ECM biocompatible protein that can be 
used as a surrogate scaffold protein. At physiological condi-
tions, amelogenin self-assembles into globular aggregates up 
to micron-sizes. When applied to the wound bed it provides 
a temporary matrix for cell attachment and promotes wound 
healing. Amelogenin has been used successfully to treat 
patients with hard-to-heal VLUs and other chronic wound 
types. A summary of the experimental and clinical data 
relating to amelogenin is presented below.Clinical Interventions in Aging 2008:3(2) 265
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In vitro studies
Amelogenin has been used in periodontal applications for 
some time and there a number of experimental and clinical 
studies supporting its use in this application. Amelogenin 
has been used as a therapy for the regeneration of alveolar 
bone by inducing the formation of acellular extrinsic ﬁ  ber 
cementum (Kim et al 2005). This protein has also been 
used to aid in soft tissue root coverage where it has been 
shown to enhance cellular activity during healing and 
improve periodontal regeneration (Giannobile and Somer-
man 2003; Young 2003). More recently, it has been shown 
that the combination of amelogenin and platelet-derived 
growth factor-BB (PDGF-BB) stimulated proliferation 
of primary human periodontal ligament ﬁ  broblasts and 
caused enhanced wound ﬁ  ll in an in vitro model (Chong 
et al 2006).
Experimental studies designed to elucidate the mecha-
nism by which amelogenin works have shown that it interacts 
with a variety of cells and chemical messengers involved 
in the wound healing process. The studies indicate that 
amelogenin can reduce levels of pro-inﬂ  ammatory cytokines 
(Myhre et al 2006).
One of the main cells involved in the healing process is 
the ﬁ  broblast. This cell synthesizes matrix components (eg, 
collagen) that are designed to ﬁ  ll the wound cavity and a 
variety of cell signals that modulate many different cellular 
responses such as angiogenesis and epithelialization. In 
experimental studies, amelogenin has been shown to:
•   augment  ﬁ  broblast-driven collagen matrix remodeling, 
increase dermal contraction and ﬁ  broblast proliferation 
(Grayson et al 2006)
•   increase synthesis of growth factors, eg, transforming growth 
factor-β1 (Grayson et al 2006) and vascular endothelial 
growth factor (Mirastschijski et al 2004)
•    convert chronic ﬁ  broblasts into acute ﬁ  broblast pheno-
types, and the restitution of proliferation and chemokine 
expression favoring an acute inﬂ  ammatory response.
Amelogenin has also been shown to be effective in inducing 
an angiogenic response in a variety of in vitro models (Yuan 
et al 2003; Schlueter et al 2007; Ågren and Kleinman 2007). 
Angiogenesis, a key component of the healing process, is sig-
niﬁ  cantly reduced in the chronic wound (Drinkwater et al 2002; 
Ulrich et al 2005), thereby affecting the healing response.
Clinical evaluations
Venous ulcers
The fact that amelogenin can be used as a temporary 
ECM protein scaffold provides a sound basis for its use 
in the treatment of wounds, particularly chronic wounds 
that are deﬁ  cient in normal ECM components. It was, 
therefore, proposed that amelogenin could be used to 
treat hard-to-heal VLUs. Initially, a preliminary clinical 
study was undertaken to ascertain the optimum number of 
applications of amelogenin (Xelma®, Molnlycke Health 
Care, Gothenburg, Sweden) that are required to be applied 
to a VLU to produce a healing response. The study compared 
once weekly applications of amelogenin in conjunction with 
high compression therapy to the hard-to-heal VLUs (dura-
tion 6 months) of patients over 3, 6 and 12 week periods 
(Romanelli et al 2006) The wounds were assessed every 
second week up to week 8, at ﬁ  nal visit (week 12), and at 
follow-up visit (12 weeks after the ﬁ  nal visit). Ulcers were 
traced and reduction in size was determined by using digital 
planimetry. The results showed that patients who received 
the 12-weeks treatment had a larger ulcer reduction (−72%) 
compared with patients who received the 3 or 6-weeks 
(−22 and −48% respectively) treatment with amelogenin 
(Figure 1 and Table 1).
The results of this preliminary study showed that hard-to-
heal VLUs elicited a positive healing response to a deﬁ  ned 
period (ie, 12 weeks) treatment with amelogenin. Using this 
information, a single-blinded, randomized, multi-centre study 
involving 117 patients was undertaken to assess the effect of 
amelogenin on hard-to-heal VLUs (Vowden et al 2006).
To satisfy the inclusion criteria for the study, patients 
had to have a VLU with a size between 5 and 25 cm2 and 
duration of at least six months that had been treated with 
controlled compression therapy for at least one month prior 
to enrolment. Patients were randomised to receive either 
amelogenin (Xelma®, Molnlycke Health Care, Gothenburg, 
Sweden) plus high compression (n = 62) or a control treat-
ment consisting of a placebo gel (the amelogenin carrier 
vehicle) plus high compression (n = 61). The amelogenin 
was applied weekly under secondary dressings for up to a 
maximum of 12 weeks. Although no statistical differences 
could be identiﬁ  ed between the groups as a whole, the per-
centage wound size reduction was greater in the group treated 
with amelogenin. A more detailed sub-group analysis was 
undertaken on patients with ulcers of greater than 10 cm2 at 
baseline and for ulcers of duration greater than 6 months. 
The results of this analysis demonstrated that there was 
a difference in percentage wound reduction in the group 
treated with amelogenin (33.8% vs 25.6%, respectively). 
It was highlighted that this difference was greatest for the 
group of patients (n = 61) with the larger ulcers (10 cm2) 
(amelogenin 25% vs control 7.9%) (Figure 2).Clinical Interventions in Aging 2008:3(2) 266
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Overall the results of this study showed that amelogenin 
was well tolerated by the patients, with a trend towards less 
pain and a reduction in the volume of exudate produced by 
the ulcers in favor of the group treated with amelogenin. 
This study highlighted the problems associated with 
undertaking clinical trials involving VLUs, the main ones 
being the wide variations in wound demographics (eg, sizes 
and ages) and their response to treatments. In future clinical 
studies, this might be overcome by stratifying the wounds 
accordingly. In addition, there was a signiﬁ  cant amount 
of variation between the pre-study treatment regimens 
employed at different centers, a phenomenon which if not 
accounted for by allowing a run-in period, may alter the 
outcome of a clinical trial. As such, the authors concluded 
that amelogenin could be clinically useful in the treatment 
of patients with ulcers that could be classiﬁ  ed as hard-to-
heal (eg, of duration longer than 6 months and a size greater 
than 10 cm2).
Another clinical trial was undertaken using the lessons 
learnt from the previous study: this was an open, random-
ized, comparative, parallel group, multi-centre study involv-
ing patients with hard-to-heal VLUs (Vowden et al 2007). 
The inclusion criteria incorporated ulcer size of greater 
than 10 cm2 and duration of longer than 6 months, both of 
which have previously been reported in the literature as 
prognostic indicators of venous ulcers that are unlikely to 
respond to treatment and may be classed as hard-to-heal 
(European Wound Management Association 2002). The 
primary objective of this study was to compare the results 
of 12 consecutive weeks of treatment with amelogenin 
(Xelma®, Molnlycke Health Care, Gothenburg, Sweden) 
plus high compression versus compression therapy alone in 
hard-to-heal VLUs. Percentage reduction of wound size from 
baseline, the percentage of improved ulcers, and parameters 
such as pain related to the disease, pain at dressing changes 
and the amount and nature of exudate were evaluated. The 
safety and tolerability of amelogenin were determined in 
relation to recorded adverse events. Eligibility for inclusion 
included adult, mobile patients with ‘hard-to-heal’ VLUs 
Table 1 Percentage change in VLU size following 3, 6 and 12 weeks 
of treatment with amelogenin. Copyright © 2006. Reproduced with 
permission from Romanelli M, Ellervee T, Jarve H, et al 2006. Amelo-
genins (Xelma®) in hard-to-heal venous leg ulcers, an open regime 
investigation [poster]. European Wound Management Association 
Conference, Prague, Czech Republic
Regimen  % Change in ulcer size
 Median  [Q1  Q3]
3 weeks, n = 10  −22.4 [−72.5−15.3]
6 weeks, n = 7  −48 [−82.1−31.3]
12 weeks, n = 12  −72 [−83.9 0.3]
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Figure 1 Percentage change in VLU size following 3, 6 and 12 weeks of treatment with amelogenin. Copyright © 2006. Reproduced with permission from Romanelli M, Ellervee 
T, Jarve H, et al 2006. Amelogenins (Xelma®) in hard-to-heal venous leg ulcers, an open regime investigation [poster]. European Wound Management Association Conference, 
Prague, Czech Republic.Clinical Interventions in Aging 2008:3(2) 267
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that had been treated with compression therapy for at least 
1 month prior to screening. The ulcers had to be at least 
6 months old, with a surface area at inclusion of at least 
10 cm2, but not exceeding 30 cm2, and not demonstrating 
excessive exudate or signs of infection. At the end of the 
run in period additional criteria for eligibility, eg, change in 
wound area (increase/decrease) of greater than or equal to 
50% and a wound area between 8 and 36 cm2 were applied. 
In total, 83 patients were randomized to receive either amelo-
genin plus high compression bandaging (n = 42) or high com-
pression bandaging (control) alone (n = 41). All participants 
received high compression bandaging therapy one month 
prior to, during the investigational period of 3-weeks run-in 
and throughout the 12 weeks of active treatment
The results of this study demonstrated that the amelo-
genin group showed a greater percentage reduction in 
ulcer size (mean −33.11%) compared to the control group 
(mean −11.07%) from baseline to the last visit (p = 0.03). The 
number of ulcers showing an improvement was signiﬁ  cantly 
greater (p = 0.01) in the amelogenin treated group than the 
control group. Statistically signiﬁ  cant differences in favor 
of the amelogenin group were also found the proportion of 
patients with none or low levels of exudate (p = 0.01).
Pain was evaluated in this study as related to the disease 
or to the ulcer. It was evaluated as part of the protocol by 
interviewing the patients who were asked to rate their pain on 
a scale with 11 steps; from 0 = no pain to 10 = unbearable pain 
(Hartrick et al 2003). The results showed that a reduction in 
pain related to the disease and a reduction in pain at dressing 
change were more apparent in the amelogenin treated group. 
Statistical analysis showed that the amelogenin group had 
signiﬁ  cantly (p = 0.01) greater ulcer pain reduction. The 
mean and 95% CI for the difference between the amelogenin 
and the control group at ﬁ  nal visit was −1.59 (−2.84 −0.34). 
Pain is considered to be a signiﬁ  cant problem in relation 
to patients with VLUs, and has been highlighted as cause 
for major concern when treating patients (Price et al 2007). 
The European Wound Management Association (2002) has 
developed a position document that provides clinical recom-
mendations to assess and manage wound pain, especially at 
dressing change. Pain management has therefore become a 
major part of wound care with many organizations and care 
providers incorporating pain management into standards, 
guidelines and clinical practice (Price et al 1997; Young 
2007). Thus the fact that amelogenin therapy, in a way as yet 
undetermined, was shown to signiﬁ  cantly reduce the pain that 
patients with hard-to-heal VLUs experienced is noteworthy 
and perhaps requires further investigation.
As well as the study participants having hard-to-heal 
wounds, the population evaluated represents possibly the 
“worst case scenario” patients, eg, some patients within the 
amelogenin group had very old ulcers (10 years or more). 
This highlights the potential advantages of using advanced 
therapies for the treatment of ulcers within this patient 
Figure 2 Median wound size reduction in the ITT population and sub-group ITTs following treatment with amelogenin and control. Copyright © 2006. Reproduced with 
permission from Vowden P, Romanelli M, Peter R, et al 2006. The effect of amelogenins (Xelma®) on hard-to-heal venous leg ulcers. Wound Rep Reg, 14:243–6.
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population. The safety of amelogenin has been established by 
completing the extensive testing that is required for medical 
devices. The safety proﬁ  le of amelogenin is underlined by 
the results of this study with few adverse events reported, 
and no signiﬁ  cant difference between the treatment and 
control groups.
A series of case studies has been presented in which a 
number of patients with hard-to-heal VLUs were treated with 
amelogenin (Xelma®, Molnlycke Health Care, Gothenburg, 
Sweden) therapy (Huldt-Nystrom et al 2007). The healing 
of these wounds was evaluated by comparing the wound 
area at baseline (before treatment) and upon completion of 
treatment. In this study, the amelogenin was applied to a 
clean wound bed, on a weekly basis, up to a maximum of 
12 weeks in conjunction with standard compression therapy. 
Some of these patients were treated with compression for 
four weeks prior to being included in the evaluations, in 
order to ensure that ulcers were truly nonhealing. The results 
showed that the success rate with amelogenin therapy was 
high, with approximately 80% of the ulcers either healing 
(60%) or showing a reduction in ulcer size (20%) after 
treatment. Only two ulcers (10%) remained unchanged and 
two ulcers deteriorated (10%) during the treatment period. 
Pseudomonas colonization/infection was present in some 
wounds after treatment had been started, but this was treated 
with appropriate antibiotic therapy, and did not affect the 
successful healing outcome of the wounds.
A small study in the United Kingdom (Acton 2007) has 
demonstrated similar results in that amelogenin (Xelma®, 
Molnlycke Health Care, Gothenburg, Sweden) stimulated 
a healing response. Even if the wounds did not progress 
to complete healing, they were signiﬁ  cantly healthier than 
before the amelogenin treatment had started and were able to 
go on to be grafted. In addition, an improvement in quality 
of life was observed in the patients who received amelogenin 
therapy.
Another study undertaken in the United Kingdom evalu-
ated amelogenin for the treatment of patients (n = 17) with a 
variety of complex hard-to-heal ulcers, including rheumatoid 
ulcers (n = 2), wounds complicated by rheumatoid arthritis 
(n = 3), neuropathic foot ulcers (n = 4), venous ulcers (n = 4), 
and a single ulcer of mixed etiology. The results from this 
study followed a similar trend to that seen in the treatment 
of other hard-to-heal ulcers, in that an early reduction in 
wound pain and exudate were apparent. Overall, six wounds 
healed after a mean of 8 applications of (Xelma®, Molnlycke 
Health Care, Gothenburg, Sweden) (range 3–16 applica-
tions), six patients showed an improvement of a greater than 
50% reduction in ulcer size, and were continuing to receive 
amelogenin therapy. Only two patients were discontinued due 
to infection and wound deterioration (Vowden et al 2007a).
In a case study series involving eight patients with a 
total of 10 VLUs (mean duration of 9.3 years), amelogenin 
(Xelma®, Molnlycke Health Care, Gothenburg, Sweden) was 
applied weekly and covered with a secondary dressing. Treat-
ment duration with amelogenin was 12 weeks and patients 
were followed up for a period of 24 weeks. An overall healing 
rate of 50% was reported, including one patient with a wound 
duration of 65 years. The other ulcers were in a healing state 
at 24 weeks, with a mean reduction in size of 60% compared 
with baseline values. Exudate levels and wound odor also 
reduced over the treatment period (Hampton et al 2007).
Diabetic ulcers
Amelogenin has recently been evaluated in a study consist-
ing of a mixed population of patients with both diabetic foot 
ulcers (n = 5) and VLUs (n = 5). Both sets of patients dem-
onstrated initiation of healing with a high percentage (80%) 
of ulcers healing completely (Meuleneire 2007). Diabetic 
foot ulcers have a different aetiology to that of VLUs, they 
are a signiﬁ  cant complication of diabetes mellitus and often 
precede lower-extremity amputation. The most frequent 
underlying aetiologies are neuropathy, trauma, deformity, 
high plantar pressures, and peripheral arterial disease. The 
primary treatment is usually ofﬂ  oading to reduce pressure to 
the sensitive areas and then management of the wound with 
appropriate dressings. Infection and high levels of wound 
exudate may be complicating factors in the treatment of 
these wounds, but the early indications are that amelogenin 
therapy, in conjunction with appropriate wound management 
techniques, can be beneﬁ  cial.
Pyoderma gangrenosum
Pyoderma gangrenosum (PG) is an inﬂ  ammatory ulcerative 
condition of unknown etiology, although an autoimmune 
mechanism including immune complex-mediated neutro-
philic vascular reactions has been suggested. PG is frequently 
associated with various diseases, but up to 50% of cases 
are idiopathic. It is a disease that causes tissue to become 
necrotic, causing deep ulcers that usually occur on the legs. 
When they occur, they can lead to chronic wounds. There 
are two main types of ulcers that occur: the normal ulcerative 
form which occurs on the legs, and an ‘atypical’ form that 
is more superﬁ  cial and occurs on the hands and other parts 
of the body. Though the etiology is not well understood, the 
disease is thought to be due to immune system dysfunction Clinical Interventions in Aging 2008:3(2) 269
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and, in particular, improper functioning of neutrophils. At 
least half of all PG patients also suffer from illnesses that 
affect their systemic function. Classical ulcerative PG is 
characterized by the appearance of nodules with pustules 
that enlarge and lead to chronic ulcers violaceous and under-
mined borders (Dini et al 2007) Amelogenin therapy has 
been used to treat two female patients with recalcitrant PG 
of the lower leg lasting an average of 11 months (Dini et al 
2007a). The treatment was applied weekly under an occlu-
sive dressing for a maximum of 8 weeks in conjunction with 
systemic immunosuppressive therapy before and during the 
topical treatment. The lesions improved, showing advances 
in granulation tissue formation and wound size reduction 
(Figures 3a-c). Additionally, pain control was reported and 
the therapy was well-tolerated with no adverse effects.
The clinical evidence suggests that in order for 
advanced therapies like amelogenin to be cost effective in 
for example the treatment of VLUs, then suitable patients 
must be carefully identiﬁ  ed and according to prognostic 
indicators of delayed healing such as wound size (larger than 
10 cm2) and wound age (duration of greater than 6 months). 
Additionally, if wounds do not show a decrease in size of 
40% or more during 4 weeks of compression therapy, then 
these wounds can be identiﬁ  ed as hard-to-heal (Phillips et al 
2000) and consideration should be given to their treatment 
with advanced therapies such as amelogenin. Compression 
therapy in conjunction with amelogenin is thought to be an 
essential adjunctive treatment. This is because it treats the 
underlying cause of venous hypertension and enables blood 
to be returned from the lower limbs, thereby reducing oedema 
and the consequences of stasis.
Infection in the wound must be treated prior to applica-
tion of amelogenin, although it has been seen that concur-
rent treatment of infection with antibacterial therapy is not 
detrimental to the amelogenin protein as a therapeutic agent. 
Additionally, wounds that exudate highly do not appear to 
beneﬁ  t as well from amelogenin therapy as wounds that have 
low to moderate levels of exudate, implicit in this therefore 
is the requirement that exudate should be managed with 
compression and appropriate dressings that can absorb the 
ﬂ  uid. Wound bed preparation is of vital importance. Dead, 
sloughy and necrotic tissue is prevalent in chronic venous 
Figure 3a Pyoderma gangrenosum at baseline before amelogenin application.Clinical Interventions in Aging 2008:3(2) 270
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Figure 3b Same lesion after eight weeks of amelogenin treatment.
Figure 3c Same lesion at 12 weeks follow up.Clinical Interventions in Aging 2008:3(2) 271
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ulcers. This tissue impedes the growth of healthy granulation 
tissue and re-epithelisation and therefore must be removed. 
This is standard practice in the treatment of such wounds. 
It is also thought that the presence of such dead tissue may 
prevent the amelogenin protein integrating into the fabric of 
the wound bed and thus providing the temporary scaffolding 
to which cells can attach and subsequently stimulate the 
healing process.
Qualitatively, VLUs treated with amelogenin appear to heal 
much better than with high compression alone, with no evidence 
of hypertrophic scarring or excessive wound contracture.
Conclusions
There is a raft of experimental evidence that supports a mecha-
nism for amelogenin in facilitating the wound healing process. 
For example, it appears that amelogenin provides a temporary 
scaffold to allow cellular adherence of ﬁ  broblasts and epithe-
lial cells. This in turn will stimulate various functions of cells 
with regards to the wound healing process, eg, migration (into 
the wound), proliferation (increasing the number of cells and 
ﬁ  lling the wound), and synthesis of mediators (growth factors 
and cytokines) that can regulate processes that are relevant 
to wound healing such as angiogenesis.
This review highlights that a number of well controlled 
trials have established that amelogenin treatment has a sta-
tistically beneﬁ  cial effect in the clinical environment. It has 
been shown that amelogenin can signiﬁ  cantly reduce ulcer 
size and also signiﬁ  cantly increase the number of patients 
showing a greater than 50% reduction in wound size, com-
pared with comparator controls. Pain is a problem in patients 
with VLUs, but it has been shown that amelogenin therapy 
can reduce the level of pain experienced by patients with 
hard-to-heal VLUs, compared with comparator controls. 
It is interesting to conjecture whether this is simply due to 
healing of the wound or whether amelogenin has a direct 
remedial effect upon pain, future studies may elucidate this 
mechanism.
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